You just read:

Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by Innovent and IASO BIO Presented at the 2019 ASH Annual Meeting

News provided by

Innovent Biologics, Inc.

Dec 10, 2019, 03:00 ET